title: Gene silencing of complement C5a receptor using siRNA for preventing ischemia/reperfusion injury.
abstract: Ischemia/reperfusion (I/R) injury in organ transplantation significantly contributes to graft failure and is untreatable using current approaches. I/R injury is associated with activation of the complement system, leading to the release of anaphylatoxins, such as C5a, and the formation of the membrane attack complex. Here, we report a novel therapy for kidney I/R injury through silencing of the C5a receptor (C5aR) gene using siRNA. Mice were injected with 50 microg of C5aR siRNA 2 days before induction of ischemia. Renal ischemia was then induced through clamping of the renal vein and artery of the left kidney for 25 minutes. The therapeutic effects of siRNA on I/R were evaluated by assessment of renal function, histopathology, and inflammatory cytokines. siRNA targeting C5aR efficiently inhibited C5aR gene expression both in vitro and in vivo. Administering C5aR siRNA to mice preserved renal function from I/R injury, as evidenced by reduced levels of serum creatinine and blood urea nitrogen in the treated groups. Inhibition of C5aR also diminished in vivo production of the pro-inflammatory cytokine tumor necrosis factor-alpha and chemokines MIP-2 and KC, resulting in the reduction of neutrophils influx and cell necrosis in renal tissues. This study demonstrates that siRNA administration represents a novel approach to preventing renal I/R injury and may be used in a variety of clinical settings, including transplantation and acute tubular necrosis.
authors.affiliation: Department of Surgery, University of Western Ontario, London, Ontario, Canada.
authors.forename: Xiufen
authors.initials: X
authors.lastname: Zheng
authors.forename: Xusheng
authors.initials: X
authors.lastname: Zhang
authors.forename: Biao
authors.initials: B
authors.lastname: Feng
authors.forename: Hongtao
authors.initials: H
authors.lastname: Sun
authors.forename: Motohiko
authors.initials: M
authors.lastname: Suzuki
authors.forename: Thomas
authors.initials: T
authors.lastname: Ichim
authors.forename: Norihiko
authors.initials: N
authors.lastname: Kubo
authors.forename: Arthur
authors.initials: A
authors.lastname: Wong
authors.forename: Lisa R
authors.initials: LR
authors.lastname: Min
authors.forename: Marianne E
authors.initials: ME
authors.lastname: Budohn
authors.forename: Bertha
authors.initials: B
authors.lastname: Garcia
authors.forename: Anthony M
authors.initials: AM
authors.lastname: Jevnikar
authors.forename: Wei-Ping
authors.initials: WP
authors.lastname: Min
mesh_terms: D000818:Animals; D001806:Blood Urea Nitrogen; D002460:Cell Line; D054426:Chemokine CXCL2 / Q000235:genetics / Q000378:metabolism; D003404:Creatinine / Q000097:blood; D015536:Down-Regulation; D020868:Gene Silencing; D007668:Kidney / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D007677:Kidney Function Tests; D008297:Male; D051379:Mice; D034741:RNA, Small Interfering / Q000378:metabolism*; D044087:Receptor, Anaphylatoxin C5a / Q000235:genetics*; D015427:Reperfusion Injury / Q000503:physiopathology / Q000517:prevention & control*; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000378:metabolism; D015854:Up-Regulation
chemical_list: D054426:Chemokine CXCL2; D034741:RNA, Small Interfering; D044087:Receptor, Anaphylatoxin C5a; D014409:Tumor Necrosis Factor-alpha; D003404:Creatinine
references.citation: J Immunol. 1999 Apr 1;162(7):4336-41
references.pmid: 10201966
references.citation: J Am Soc Nephrol. 2006 Mar;17(3):707-15
references.pmid: 16467447
references.citation: Am J Transplant. 2006 Sep;6(9):2099-108
references.pmid: 16796725
references.citation: Transplantation. 2006 Dec 27;82(12):1781-6
references.pmid: 17198276
references.citation: J Surg Res. 2004 Jan;116(1):81-90
references.pmid: 14732352
references.citation: Scand J Immunol. 2005 May;61(5):426-34
references.pmid: 15882434
references.citation: Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7797-802
references.pmid: 12810955
references.citation: J Immunol. 2003 Feb 1;170(3):1517-23
references.pmid: 12538716
references.citation: Nat Genet. 2002 Sep;32(1):107-8
references.pmid: 12145662
references.citation: Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16969-74
references.pmid: 12477926
references.citation: J Clin Invest. 2000 May;105(10):1363-71
references.pmid: 10811844
references.citation: Am J Pathol. 2004 Nov;165(5):1677-88
references.pmid: 15509537
references.citation: Arthritis Rheum. 2001 Oct;44(10):2425-34
references.pmid: 11665985
references.citation: Am J Pathol. 2004 Sep;165(3):825-32
references.pmid: 15331407
references.citation: J Clin Invest. 2003 Mar;111(6):877-85
references.pmid: 12639994
references.citation: Pediatr Res. 2000 Aug;48(2):200-5
references.pmid: 10926295
references.citation: J Immunol. 2003 Apr 1;170(7):3883-9
references.pmid: 12646657
references.citation: Kidney Int. 2003 Jan;63(1):134-42
references.pmid: 12472776
references.citation: Transplantation. 2003 Feb 15;75(3):375-82
references.pmid: 12589162
references.citation: Transplantation. 2006 Dec 27;82(12):1728-32
references.pmid: 17198267
references.citation: Gastroenterology. 2001 Jan;120(1):126-33
references.pmid: 11208721
references.citation: J Immunol. 2004 Mar 15;172(6):3869-75
references.pmid: 15004194
references.citation: Nature. 2002 Jul 4;418(6893):38-9
references.pmid: 12097900
references.citation: Surgery. 2004 Aug;136(2):390-400
references.pmid: 15300206
references.citation: J Biol Chem. 2005 Jul 1;280(26):24396-403
references.pmid: 15863508
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2007 Oct;376(1-2):1-43
references.pmid: 18038125
references.citation: J Immunol. 2007 Feb 1;178(3):1819-28
references.pmid: 17237432
references.citation: Shock. 2004 May;21(5):401-9
references.pmid: 15087815
references.citation: Am J Transplant. 2004 Aug;4(8):1227-36
references.pmid: 15268723
references.citation: Clin Exp Immunol. 2008 Jul;153(1):117-26
references.pmid: 18505432